Development of a fragment-based screening assay for the focal adhesion targeting domain using SPR and NMR

Carlos Alvarado, Erik Stahl, Karissa Koessel, Andrew Rivera, Brian Cherry, Surya V.S.R.K. Pulavarti, Thomas Szyperski, William Cance, Timothy Marlowe

Research output: Contribution to journalArticle

Abstract

The Focal Adhesion Targeting (FAT) domain of Focal Adhesion Kinase (FAK) is a promising drug target since FAK is overexpressed in many malignancies and promotes cancer cell metastasis. The FAT domain serves as a scaffolding protein, and its interaction with the protein paxillin localizes FAK to focal adhesions. Various studies have highlighted the importance of FAT-paxillin binding in tumor growth, cell invasion, and metastasis. Targeting this interaction through high-throughput screening (HTS) provides a challenge due to the large and complex binding interface. In this report, we describe a novel approach to targeting FAT through fragment-based drug discovery (FBDD). We developed two fragment-based screening assays—a primary SPR assay and a secondary heteronuclear single quantum coherence nuclear magnetic resonance (HSQC-NMR) assay. For SPR, we designed an AviTag construct, optimized SPR buffer conditions, and created mutant controls. For NMR, resonance backbone assignments of the human FAT domain were obtained for the HSQC assay. A 189-compound fragment library from Enamine was screened through our primary SPR assay to demonstrate the feasibility of a FAT-FBDD pipeline, with 19 initial hit compounds. A final total of 11 validated hits were identified after secondary screening on NMR. This screening pipeline is the first FBDD screen of the FAT domain reported and represents a valid method for further drug discovery efforts on this difficult target.

Original languageEnglish (US)
Article number3352
JournalMolecules
Volume24
Issue number18
DOIs
StatePublished - Sep 14 2019

Fingerprint

Focal Adhesions
Assays
Screening
adhesion
screening
Adhesion
Nuclear magnetic resonance
fragments
nuclear magnetic resonance
Drug Discovery
Focal Adhesion Protein-Tyrosine Kinases
drugs
Paxillin
metastasis
Pipelines
Neoplasm Metastasis
Neoplasms
Cell growth
proteins
Tumors

Keywords

  • FAT domain
  • Focal adhesion kinase
  • Fragment-based drug discovery
  • Nuclear magnetic resonance
  • Surface plasmon resonance

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Cite this

Alvarado, C., Stahl, E., Koessel, K., Rivera, A., Cherry, B., Pulavarti, S. V. S. R. K., ... Marlowe, T. (2019). Development of a fragment-based screening assay for the focal adhesion targeting domain using SPR and NMR. Molecules, 24(18), [3352]. https://doi.org/10.3390/molecules24183352

Development of a fragment-based screening assay for the focal adhesion targeting domain using SPR and NMR. / Alvarado, Carlos; Stahl, Erik; Koessel, Karissa; Rivera, Andrew; Cherry, Brian; Pulavarti, Surya V.S.R.K.; Szyperski, Thomas; Cance, William; Marlowe, Timothy.

In: Molecules, Vol. 24, No. 18, 3352, 14.09.2019.

Research output: Contribution to journalArticle

Alvarado, C, Stahl, E, Koessel, K, Rivera, A, Cherry, B, Pulavarti, SVSRK, Szyperski, T, Cance, W & Marlowe, T 2019, 'Development of a fragment-based screening assay for the focal adhesion targeting domain using SPR and NMR', Molecules, vol. 24, no. 18, 3352. https://doi.org/10.3390/molecules24183352
Alvarado C, Stahl E, Koessel K, Rivera A, Cherry B, Pulavarti SVSRK et al. Development of a fragment-based screening assay for the focal adhesion targeting domain using SPR and NMR. Molecules. 2019 Sep 14;24(18). 3352. https://doi.org/10.3390/molecules24183352
Alvarado, Carlos ; Stahl, Erik ; Koessel, Karissa ; Rivera, Andrew ; Cherry, Brian ; Pulavarti, Surya V.S.R.K. ; Szyperski, Thomas ; Cance, William ; Marlowe, Timothy. / Development of a fragment-based screening assay for the focal adhesion targeting domain using SPR and NMR. In: Molecules. 2019 ; Vol. 24, No. 18.
@article{a6a932cf746242c99dc712b4a7c1fa8e,
title = "Development of a fragment-based screening assay for the focal adhesion targeting domain using SPR and NMR",
abstract = "The Focal Adhesion Targeting (FAT) domain of Focal Adhesion Kinase (FAK) is a promising drug target since FAK is overexpressed in many malignancies and promotes cancer cell metastasis. The FAT domain serves as a scaffolding protein, and its interaction with the protein paxillin localizes FAK to focal adhesions. Various studies have highlighted the importance of FAT-paxillin binding in tumor growth, cell invasion, and metastasis. Targeting this interaction through high-throughput screening (HTS) provides a challenge due to the large and complex binding interface. In this report, we describe a novel approach to targeting FAT through fragment-based drug discovery (FBDD). We developed two fragment-based screening assays—a primary SPR assay and a secondary heteronuclear single quantum coherence nuclear magnetic resonance (HSQC-NMR) assay. For SPR, we designed an AviTag construct, optimized SPR buffer conditions, and created mutant controls. For NMR, resonance backbone assignments of the human FAT domain were obtained for the HSQC assay. A 189-compound fragment library from Enamine was screened through our primary SPR assay to demonstrate the feasibility of a FAT-FBDD pipeline, with 19 initial hit compounds. A final total of 11 validated hits were identified after secondary screening on NMR. This screening pipeline is the first FBDD screen of the FAT domain reported and represents a valid method for further drug discovery efforts on this difficult target.",
keywords = "FAT domain, Focal adhesion kinase, Fragment-based drug discovery, Nuclear magnetic resonance, Surface plasmon resonance",
author = "Carlos Alvarado and Erik Stahl and Karissa Koessel and Andrew Rivera and Brian Cherry and Pulavarti, {Surya V.S.R.K.} and Thomas Szyperski and William Cance and Timothy Marlowe",
year = "2019",
month = "9",
day = "14",
doi = "10.3390/molecules24183352",
language = "English (US)",
volume = "24",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "18",

}

TY - JOUR

T1 - Development of a fragment-based screening assay for the focal adhesion targeting domain using SPR and NMR

AU - Alvarado, Carlos

AU - Stahl, Erik

AU - Koessel, Karissa

AU - Rivera, Andrew

AU - Cherry, Brian

AU - Pulavarti, Surya V.S.R.K.

AU - Szyperski, Thomas

AU - Cance, William

AU - Marlowe, Timothy

PY - 2019/9/14

Y1 - 2019/9/14

N2 - The Focal Adhesion Targeting (FAT) domain of Focal Adhesion Kinase (FAK) is a promising drug target since FAK is overexpressed in many malignancies and promotes cancer cell metastasis. The FAT domain serves as a scaffolding protein, and its interaction with the protein paxillin localizes FAK to focal adhesions. Various studies have highlighted the importance of FAT-paxillin binding in tumor growth, cell invasion, and metastasis. Targeting this interaction through high-throughput screening (HTS) provides a challenge due to the large and complex binding interface. In this report, we describe a novel approach to targeting FAT through fragment-based drug discovery (FBDD). We developed two fragment-based screening assays—a primary SPR assay and a secondary heteronuclear single quantum coherence nuclear magnetic resonance (HSQC-NMR) assay. For SPR, we designed an AviTag construct, optimized SPR buffer conditions, and created mutant controls. For NMR, resonance backbone assignments of the human FAT domain were obtained for the HSQC assay. A 189-compound fragment library from Enamine was screened through our primary SPR assay to demonstrate the feasibility of a FAT-FBDD pipeline, with 19 initial hit compounds. A final total of 11 validated hits were identified after secondary screening on NMR. This screening pipeline is the first FBDD screen of the FAT domain reported and represents a valid method for further drug discovery efforts on this difficult target.

AB - The Focal Adhesion Targeting (FAT) domain of Focal Adhesion Kinase (FAK) is a promising drug target since FAK is overexpressed in many malignancies and promotes cancer cell metastasis. The FAT domain serves as a scaffolding protein, and its interaction with the protein paxillin localizes FAK to focal adhesions. Various studies have highlighted the importance of FAT-paxillin binding in tumor growth, cell invasion, and metastasis. Targeting this interaction through high-throughput screening (HTS) provides a challenge due to the large and complex binding interface. In this report, we describe a novel approach to targeting FAT through fragment-based drug discovery (FBDD). We developed two fragment-based screening assays—a primary SPR assay and a secondary heteronuclear single quantum coherence nuclear magnetic resonance (HSQC-NMR) assay. For SPR, we designed an AviTag construct, optimized SPR buffer conditions, and created mutant controls. For NMR, resonance backbone assignments of the human FAT domain were obtained for the HSQC assay. A 189-compound fragment library from Enamine was screened through our primary SPR assay to demonstrate the feasibility of a FAT-FBDD pipeline, with 19 initial hit compounds. A final total of 11 validated hits were identified after secondary screening on NMR. This screening pipeline is the first FBDD screen of the FAT domain reported and represents a valid method for further drug discovery efforts on this difficult target.

KW - FAT domain

KW - Focal adhesion kinase

KW - Fragment-based drug discovery

KW - Nuclear magnetic resonance

KW - Surface plasmon resonance

UR - http://www.scopus.com/inward/record.url?scp=85072289731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072289731&partnerID=8YFLogxK

U2 - 10.3390/molecules24183352

DO - 10.3390/molecules24183352

M3 - Article

C2 - 31540099

AN - SCOPUS:85072289731

VL - 24

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 18

M1 - 3352

ER -